Pear Therapeutics Advisor, Patrick J. Kennedy, to speak at Cambridge Public Library on Thursday, October 22, 2015 at 7:00pm
Harvard Book Store will welcome former congressman, Patrick J. Kennedy, for a discussion of his book A Common Struggle: A Personal Journey Through the Past and Future of Mental Illness and Addiction, co-authored with Stephen Fried.
Cambridge Public Library
Cambridge, MA 02138
Pear Therapeutics CEO, Corey McCann MD, PhD, was interviewed during the 3rd European Neurotech Investing and Partnering Summit held on September 9-10 in Geneva, Switzerland.
The World Medical Innovation Forum features CEOs of industry-leading multinational medical companies, Partners HealthCare top clinicians and scientists—all Harvard Medical School faculty members—and global technology leaders. Join 1,000 international innovation decision-makers and be briefed on the state of the art in neuroscience technology, care and research directly from the CEOs bringing game-changing products to market…
The Neurotechnology Industry Organization (NIO), the leading neuroscience trade association, today formally announced that its third annual NeuroGaming Conference and Expo will be held in San Francisco on May 6-7, 2015. The NeuroGaming Conference focuses on the convergence of mind and body with game play; engaging the full nervous system into the gaming experience for the purposes of entertainment, education, health and wellness…
BOSTON, MA – Pear Therapeutics, the creator of prescription pharmaceutical-software combination products called eFormulations™, announced today that it has successfully closed on additional financing. The funding round was led by 5AM Ventures, with several undisclosed additional investors contributing capital. The investment will allow Pear to build a portfolio of eFormulationsTM. Concurrently, Andrew J. Schwab, Founding Managing Partner of 5AM Ventures, has been appointed to the Pear Therapeutics Board of Directors.
Pear is developing digital health interventions to enhance the efficacy of pharmaceutical preparations. While its proprietary approach has broad clinical application, the company is initially focused on disorders of the brain, many of which impose large societal costs and yet still have limited treatment options. “From mobile applications, to virtual reality simulations, to predictive analytics, our technology directly boosts medication efficacy in incredibly significant ways, well beyond enhanced compliance. Our team has pulled together the pieces required to deliver these products to patients,” said Corey McCann, President and CEO of Pear.
“Brain-related disorders represent a significant healthcare problem that today’s pharmaceutical pipeline is ill-equipped to address. We were very impressed by early data for eFormulations™ in tackling mental health issues and Pear’s approach provides an opportunity to elevate the standard of care for disorders going well beyond the brain,” said Andrew J. Schwab.
About Pear Therapeutics
Pear Therapeutics is a privately held eHealth company with offices in Boston and San Francisco developing drug/software combination products to address a broad range of severe conditions. The company’s eFormulationTM platform combines pharmaceutical preparations with user-friendly, customizable, and scientifically validated software applications. Pear’s patented approach provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payors. For additional information please visit our website at www.peartherapeutics.com.
About 5AM Ventures
5AM Ventures actively invests in next-generation life science companies. The firm is currently investing 5AM Ventures IV, L.P., a $250 million venture capital fund that closed in 2013. With over $685 million under management, 5AM has invested in 49 early-stage companies and its successful realizations include Achaogen (Nasdaq: AKAO), Alexza Pharmaceuticals (Nasdaq: ALXA), DVS Sciences (sold to Fluidigm), Envoy Therapeutics (sold to Takeda), Flexion Therapeutics (Nasdaq: FLXN), Ikaria (sold to Madison Dearborn), Ilypsa (sold to Amgen), Incline Therapeutics (sold to The Medicines Company), Marcadia (sold to Roche), Miikana Therapeutics (sold to EntreMed), Panomics (sold to Affymetrix), Pearl Therapeutics (sold to AstraZeneca), Relypsa (Nasdaq: RLYP), Semprus (sold to Teleflex) and Synosia Therapeutics (sold to Biotie Therapies). For more information, please visit www.5amventures.com.
The phrase “better living through chemistry,” derived from an old DuPont corporate slogan, has accumulated all kinds of ironic and wink-wink connotations over the decades. But there’s a fascinating revival and upgrade underway.
For people with debilitating mental health problems, many researchers, doctors, and businesspeople think the new phrase should be “better living through chemistry and digital technology.” OK, it’s clunky, but it helps describe a range of new digital therapies—delivered via mobile apps, desktop or TV-based games, and even immersive virtual reality—under development for mental health and addiction disorders that thousands of patients have already used…
How researchers are using computer games to treat pain, aging, ADHD, and other ailments.
Feeling anxious, depressed, fearful, or unable to focus? Is your memory getting fuzzy? Medication might help. Therapy might help. And someday soon–according to neuroscientists, game designers, and drug makers–you might be prescribed a videogame that helps as much as (or more than) either. Here are a few of the innovative companies that are fusing game mechanics with principles of cognitive psychology to create a new paradigm for digital healing…
National Space Biomedical Research Institute Funds Eye Tracking Technology And Software-Enabled Therapeutics For Brain Health
The National Space Biomedical Research Institute (NSBRI) has announced funding for the EyeBoxCNS, a diagnostic device developed to assess brain health through tracking eye movement, and for eFormulations, software enabled therapeutics which combine prescription medicines with customized software apps for brain-related conditions.
Houston–The EyeBox (cns), a diagnostic device developed to assess brain health through tracking eye movement, and eFormulations, software enabled therapeutics which combine prescription medicines with customized software apps for brain-related conditions, have both been funded for further development by the National Space Biomedical Research Institute (NSBRI)…
Pear Therapeutics Presents at The 9th Annual Neurotech Investing & Partnering Conference 2014, Apr-24-2014 10:30 AM. Venue: The Ritz Carlton, 10 Avery St., Boston, Massachusetts, United States. Speakers: Corey McCann, CEO.